Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

ADC


Fundamental

Company: Agree Realty Corp
Sector: Real Estate
Industry: REIT - Retail
Country: USA
Exchange: NYSE
Index: -
P/E: 40.58
EPS (ttm): 1.77
Insider Own: 1.75%
Shs Outstand: 110.02M
Perf Week: -1.41%
Market Cap: 7.92B
Forward P/E: 36.61
EPS next Y: 1.97
Insider Trans: 2.02%
Shs Float: 108.09M
Perf Month: -3.69%
Enterprise Value: 11.11B
PEG: 8.98
EPS next Q: 0.45
Inst Own: 114.26%
Short Float: 10.58%
Perf Quarter: -5.91%
Income: 183.42M
P/S: 12.42
EPS this Y: 1.68%
Inst Trans: 7.01%
Short Ratio: 8.53
Perf Half Y: 2.95%
Sales: 637.40M
P/B: 1.45
EPS next Y Percentage: 8.62%
ROA: 2.30%
Short Interest: 11.44M
Perf YTD: 2.16%
Book/sh: 49.71
P/C: 708.87
EPS next 5Y: 4.52%
ROE: 3.54%
52W High: 79.65 -9.64%
Perf Year: 16.70%
Cash/sh: 0.10
P/FCF: 17.86
EPS past 3/5Y: -0.08% -1.65%
ROIC: 2.13%
52W Low: 61.33 17.34%
Perf 3Y: -2.01%
Dividend Est.: 3.09 (4.29%)
EV/EBITDA: 21.23
Sales past 3/5Y: 22.09% 26.92%
Gross Margin: 54.34%
Volatility W: 1.50%
Volatility M: 1.61%
Perf 5Y: 14.38%
Dividend TTM: 3.04 (4.22%)
EV/Sales: 17.42
EPS Y/Y TTM: 5.67%
Oper. Margin: 48.21%
ATR (14): 1.25
Perf 10Y: 143.31%
Dividend Ex-Date: Jun 30, 2025
Quick Ratio: 1.49
Sales Y/Y TTM: 13.75%
Profit Margin: 28.78%
RSI (14): 37.57
Recom: 1.62
Dividend Gr. 3/5Y: 4.89% 5.64%
Current Ratio: 1.49
EPS Q/Q: -2.06%
SMA20: -2.66%
Beta: 0.55
Target Price: 82.03
Payout: 168.60%
Debt/Eq: 0.54
Sales Q/Q: 13.25%
SMA50: -3.82%
Rel Volume: 0.40
Prev Close: 72.06
Employees: 75
LT Debt/Eq: 0.53
Earnings: Apr 22 AMC
SMA200: -3.17%
Avg Volume: 1.34M
Price: 71.97
IPO: Apr 15, 1994
Option/Short: Yes / Yes
EPS/Sales Surpr.: -0.62% 2.76%
Trades:
Volume: 529,957
Change: -0.12%

Technical:


Latest News:

USFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse ... very bullish
PFE

Summary: Pfizer Inc. receives FDA approval for the supplemental BLA for ADCETRIS in combination therapy for the treatment of relapsed or refractory large B-cell lymphoma, showing significant improvement in overall survival based on Phase 3 study. The therapy provides a new option for patients who have failed two prior lines of therapy.

Full article
2025-02-13T10:18:31Z
Broadcom (AVGO) Stock: AI & Tech Giant on the Rise! - INDODAX somewhat bullish
AVGO

Summary: Broadcom Inc. (AVGO) is a key player in the semiconductor and software industry known for its consistent revenue growth, strong position in developing various chips, and attractive dividend policy. The company has shown solid financial performance with high revenues and profitability, alongside an expansion strategy through acquisitions. Broadcom faces challenges from regulations, global competition, and the need for continued innovation in the semiconductor industry.

Full article
2025-02-13T03:25:17Z
Appier Announces Acquisition Agreement with AdCreative.ai to Lead Generative AI ... very bullish
4180

Summary: Appier, the AI-powered SaaS leader in AdTech and MarTech, has announced an acquisition agreement with AdCreative.ai, a Paris-based innovator in Generative AI-driven creative creation and optimization, for a total of 38.7 million USD, to accelerate Appier's Generative AI product portfolio and reshape the future of digital advertising and marketing.

Full article
2025-02-12T22:15:48Z
Broadcom Inc. (AVGO): Among the Large-Cap Stocks Insiders Are Selling Recently - Yahoo Finance neutral
AVGO

Summary: Insider Monkey compiled a list of the 10 Large-Cap Stocks Insiders Are Selling Recently. Broadcom Inc. (NASDAQ:AVGO) is one of the large-cap stocks mentioned. Insider moves can provide valuable insights into a company's potential and performance, but should be analyzed in conjunction with other factors before making investment decisions.

Full article
2025-02-12T21:20:15Z
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment ... - Yahoo Finance very bullish
PFE

Summary: Pfizer's ADCETRIS regimen receives FDA approval for adult patients with relapsed or refractory large B-cell lymphoma, demonstrating a 37% reduction in the risk of death. This marks the eighth FDA-approved indication for ADCETRIS, positioning it as a standard of care for certain lymphomas.

Full article
2025-02-12T17:28:07Z
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment ... - Business Wire very bullish
PFE

Summary: Pfizer Inc. announced that the FDA has approved ADCETRIS in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of therapy. The approval is based on positive efficacy and safety data from the Phase 3 ECHELON-3 study.

Full article
2025-02-12T17:22:58Z
The AI Revolution: Why Broadcom (AVGO) Stands Strong Amidst Market Waves very bullish
AVGO

Summary: Broadcom Inc. is experiencing remarkable growth in the AI infrastructure market, with a 51% year-over-year revenue increase in fiscal Q4 2024 and anticipated revenue of $14.6 billion in early 2025. Partnerships with tech giants like Google, Meta, and ByteDance underscore Broadcom's influence, with potential market reach to $90 billion by 2027. Analysts foresee heightened demand for Broadcom's ASICs as AI technology expands.

Full article
2025-02-12T14:41:27Z
Possible Bearish Signals With Broadcom Insiders Disposing Stock - Yahoo Finance somewhat bearish
AVGO

Summary: Several Broadcom Inc. insiders have been selling their stock over the past year, with the latest sale by Hock Tan being the biggest insider sale in the last year. Insiders did not buy any shares over the same period. Despite high insider ownership, the selling activity leaves room for caution for shareholders.

Full article
2024-09-30T11:26:30Z
Broadcom, Charter and Comcast to jointly develop unified DOCSIS 4.0 chipsets very bullish
AVGO CHTR CMCSA

Summary: Broadcom, Charter Communications, and Comcast have announced a joint development of Unified DOCSIS chipsets enabling 25 Gbps speeds over existing networks, incorporating AI/ML capabilities, improving performance, reliability, and creating economies of scale.

Full article
2024-09-30T08:15:10Z
Broadcom Inc. (AVGO) Beats Q3 Expectations but Faces Stock Decline on Weaker Q4 ... somewhat bearish
AVGO

Summary: Broadcom Inc. (AVGO) recently posted third quarter earnings that beat market expectations, but weaker-than-expected guidance for the fourth quarter led to a decline in stock value. Reports of a potential takeover bid at Intel also affected the stock, although analysts deemed it unlikely due to regulatory obstacles.

Full article
2024-09-30T07:56:31Z
TD SYNNEX Expands Broadcom Partnership for Security Solutions - Channel Insider somewhat bullish
TD

Summary: TD SYNNEX expands exclusive distribution agreement with Broadcom to include Symantec and Carbon Black portfolios in Latin America and the Caribbean (LAC) and North America. This move aims to streamline the purchasing process and enhance region-based support for both product portfolios.

Full article
2024-09-23T14:24:07Z
Broadcom announces general availability of Sian2 - TipRanks.com very bullish
AVGO

Summary: Broadcom announced the general availability of Sian2, 200 Gbps per lane PAM-4 DSP PHY, which features 200G/lane electrical and optical interfaces. Sian and Sian2 DSPs enable pluggable modules with 200G/lane interfaces to connect next generation AI clusters.

Full article
2024-09-23T13:21:45Z